Publication date: Jun 27, 2025
Zinc and copper are essential trace elements that regulate immunity and inflammation, with antiviral effects that may help combat respiratory viruses like SARS-CoV-2, the virus responsible for COVID-19. These effects include reducing cytokine storms and acute respiratory distress syndrome (ARDS). However, zinc and copper uptake is limited by homeostasis mechanisms, reducing their effectiveness. Sodium copper chlorophyllin (SCC) and sodium zinc chlorophyllin (SZC), nontoxic chlorophyll derivatives, may overcome these limitations by delivering higher intracellular levels of these metals. Evidence suggests SCC and SZC exhibit antiviral activity against SARS-CoV-2 and other respiratory viruses by inhibiting viral entry, replication, and release from infected cells. Animal studies show that SCC can lower viral loads and reduce ARDS-like symptoms. Additionally, SCC and SZC may suppress proinflammatory cytokines, potentially preventing or reducing the severity of cytokine storms. This review highlights the antiviral and anti-inflammatory effects of zinc and copper, explores the therapeutic potential of SCC and SZC in viral respiratory infections, and discusses future research directions to optimize these treatments.
| Concepts | Keywords |
|---|---|
| Future | anti-inflammatory |
| Homeostasis | antiviral |
| Therapeutic | Chlorophyllin |
| Virus | cytokine storm |
| Zinc | respiratory tract diseases |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Zinc |
| drug | DRUGBANK | Copper |
| disease | MESH | respiratory infections |
| disease | MESH | inflammation |
| disease | MESH | COVID-19 |
| disease | MESH | cytokine storms |
| disease | MESH | acute respiratory distress syndrome |
| drug | DRUGBANK | Chlorophyll A |
| disease | IDO | replication |
| pathway | REACTOME | Release |
| disease | MESH | respiratory tract diseases |